Labcorp (LH) Q2 2026 Earnings Call Transcript
Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% YoY, with adjusted EPS of $4.99, up 14.9%. Adjusted operating margin rose to 15.8%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength, and noted ACA headwinds.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue and adjusted EPS ranges, the quantified margin expansion drivers, and the explicit cash flow and reimbursement headwinds (ACA volume headwind, PAMA risk).
Market read
Traders can reprice LH on the guidance increase and margin expansion, while monitoring cash conversion and reimbursement-policy risks highlighted in the call.
What to watch
Working-capital timing and planned capex (about 4% of revenue) could keep cash conversion weak even if margins improve; also, BLS backlog conversion expectations may not fully translate into near-term cash.
Background
The transcript covers Labcorp’s Q2 2026 results, capital allocation, and updated full-year 2026 guidance across Diagnostics and Biopharma Laboratory Services.
Ticker impact
Labcorp raised full-year 2026 enterprise revenue guidance to 5.4% to 6.3% and adjusted EPS to $18.10 to $18.55, citing margin and Central Labs strength.
Near-term bias higher if investors focus on raised EPS and BLS margin expansion; downside risk if FCF weakness or ACA/PAMA headwinds dominate.
The article provides multiple forward-looking datapoints (raised revenue and EPS ranges, FCF guidance maintained) and quantifies key offsets (ACA headwind, PAMA risk, FCF down year over year).
Market effects
Supports the diagnostics and clinical lab services theme that specialty testing and central lab capacity are sustaining growth and operating leverage.
Limited direct regional read-through; impacts are primarily US healthcare services utilization and reimbursement policy sensitivity.
Moderate, via BLS international exposure and foreign-currency tailwind adjustments mentioned in growth math.
Counterpoint
FCF declined sharply year over year ($314M vs $543M) and ACA/PAMA reimbursement pressures remain, so the earnings quality may be less durable than the EPS headline suggests.
Key entities
- companyLabcorp Holdings Inc.
Reported Q2 2026 enterprise revenue growth and margin expansion, raised full-year 2026 guidance, and launched ColoSense with at-home collection.
- executiveAdam Schechter
CEO who discussed specialty testing growth and early signals for ColoSense.
- executiveJulia Wang
CFO who quantified ACA volume headwind and discussed strategic actions completion in Early Development.
